Eleusis, a private psychedelics company, has announced it is going public via a merger with Silver Spike Acquisition Corp II.
Gold prices holding gains as U.S. new home construction rises 1.4% in December
The gold market is holding in positive territory and seeing little reaction to stronger than expected U.S. housing construction data.
Awakn Life Sciences Signs MOU with Maps
Awakn and MAPS to team up to address Alcohol Use Disorder in Europe.
Levitee Labs Announces Non-Brokered Private Placement of up to $3,000,000
Levitee Labs announces a CAD$3 million private placement with units priced at CAD$0.20 and a full warrant at CAD$0.40.
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial
Numinus announces all regulatory authorization and preparations have been completed for the next stage of MAPS' clinical trial for MDMA-assisted psychotherapy.
Study Finds 65% Of Americans With Mental Health Conditions Want Access To Psychedelics
A new study conducted by The Harris Poll and Delic Holdings Corp found that 65% of affected Americans want access to psychedelics for mental health.
Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program
Mydecine signs an LOI to provide The Newly Institute with psilocybin and MDMA for use in Health Canada SAP-approved psychedelics-based therapy.
Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent
Optimi Health submits a patent application for the extraction process for its natural psilocybin extract.
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001
Better Life Pharma reports encouraging pre-clinical results for its non-hallucinogenic psychedelic analog.
Gold prices push higher following 1.9% drop in U.S. retail sales
Gold prices have pushed higher as consumers shopped less than expected in December.
Mydecine to Launch Special Access Support and Supply Program in Canada Expanding Access to Psychedelic-Assisted Psychotherapy For Patients
Mydecine seeks to become a psilocybin supplier for new applications for psilocybin-therapy under Canada's SAP.
Novamind Hosts Pioneering Psychedelic Clinical Trial for Opioid Use Disorder
Novamind to host a Phase I clinical trial of a ketamine-assisted therapy for Opioid Use Disorder.
